Vessl Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Out of Business

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Out of Business

Vessl General Information

Description

Developer of gene and cell therapy products designed to treat patients who suffer from cardiovascular and other vascular-related conditions. The company's products are used in therapies for patients with peripheral artery disease, coronary artery disease, and renal disease requiring hemodialysis, enabling healthcare providers to treat and address heart and blood vessel disorders

Contact Information

Formerly Known As
MultiGene Vascular Systems, MGVS
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Colab Square Facility
  • 6 HaYozma Street
  • Yokne'am Illit 2069203
  • Israel
+972
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Colab Square Facility
  • 6 HaYozma Street
  • Yokne'am Illit 2069203
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vessl Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Out of Business 29-May-2026 Completed Out of Business
6. Later Stage VC 25-Apr-2021 Completed Generating Revenue
5. Later Stage VC 01-Jan-2012 Completed Generating Revenue
4. Later Stage VC 27-Oct-2009 Completed Generating Revenue
3. Debt - General 01-Jan-2009 Completed Generating Revenue
2. Later Stage VC 31-Dec-2006 $6M $10M Completed Generating Revenue
1. Early Stage VC 23-May-2004 $4M $4M Completed Startup
To view Vessl’s complete valuation and funding history, request access »

Vessl Patents

Vessl Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3995569-A1 Methods of preconditioning vascular cells for transduction, methods of transduction and methods of preserving transduced cells Inactive 10-Nov-2020
US-12698477-B2 Methods of preconditioning vascular cells for transduction, methods of transduction and methods of preserving transduced cells Active 10-Nov-2020
US-20220145258-A1 Methods of preconditioning vascular cells for transduction, methods of transduction and methods of preserving transduced cells Active 10-Nov-2020
EP-3226886-A1 Use of fibulin-5 for the treatment of keloid scars Inactive 07-Dec-2014
EP-3226886-A4 Use of fibulin-5 for the treatment of keloid scars Inactive 07-Dec-2014 A61K38/1741
To view Vessl’s complete patent history, request access »

Vessl Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vessl FAQs

  • When was Vessl founded?

    Vessl was founded in 2000.

  • Where is Vessl headquartered?

    Vessl is headquartered in Yokne'am Illit, Israel.

  • What is the size of Vessl?

    Vessl has 3 total employees.

  • What industry is Vessl in?

    Vessl’s primary industry is Drug Discovery.

  • Is Vessl a private or public company?

    Vessl is a Private company.

  • What is Vessl’s current revenue?

    The current revenue for Vessl is .

  • How much funding has Vessl raised over time?

    Vessl has raised $48.5M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process